SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (15.1), the stock would be worth ₹273.31 (33% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.5 | ₹408.1 |
0%
|
| 3-Year Average | 15.1 | ₹273.31 |
-33%
|
| 5-Year Average | 13.4 | ₹242.86 |
-40%
|
| Industry Average | 21.2 | ₹384.12 |
-6%
|
| Country Average | 17.7 | ₹320.57 |
-21%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
|
38.2B INR | 22.5 | 42.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 27.8 |
| Max | 47 834.4 |
Other Multiples
SMS Pharmaceuticals Ltd
Glance View
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing active pharma ingredients (API) and their intermediates. The firm's API products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Pantoprazole Sodium Sesquihydrate US/Ph. Eur, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP, Sumatriptan Succinate USP / Ph.Eur/ BP, Sumatriptan Base USP / Ph.Eur/ BP, Almotriptan Malate, Zolmitriptan, Rizatriptan Benzoate USP/ Ph.Eur, Eletriptan Hydrobromide Monohydrate, Sildenafil Citrate USP / Ph.Eur, Tadalafil USP / Ph.Eur, Vardenafil and others. The firm's manufacturing facilities are located in Bachupally, Hyderabad in the state of Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram district in Andhra Pradesh. Its research and development (R&D) center is located in Gagillapur, Hyderabad.
